Reuters logo
2 个月前
BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate
2017年6月1日 / 中午12点20分 / 2 个月前

BRIEF-Achaogen starts C-Scape clinical development program with phase 1 study of orally-administered antibacterial candidate

1 分钟阅读

June 1 (Reuters) - Achaogen Inc

* Initiates c-scape clinical development program with phase 1 study of orally-administered antibacterial candidate

* Says preclinical studies have confirmed c-scape's potent in vitro microbiologic activity against esbl-producing enterobacteriaceae Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below